Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder

Eiji Harada,1 Osamu Shirakawa,2 Yoichi Satoi,3 Lauren B Marangell,4 Rodrigo Escobar5 1Eli Lilly Japan K.K., Medicines Development Unit Japan, Medical Science, Kobe, 2Department of Neuropsychiatry, Kinki University Faculty of Medicine, Osakasayama, 3Eli Lilly Japan K.K., Medicines Development Unit J...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Harada E, Shirakawa O, Satoi Y, Marangell LB, Escobar R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	antidepressant dose duloxetine major depressive disorder titration Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/605ed851076645a6ab46bdc7d4e1a89b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder

Ejemplares similares